coteau ARQ.

VCRE

Vicore Pharma Holding AB (publ)
$9.38
−$0.94 (9.11%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-52%-36%-21%-6%+10%Jul 6Oct 23Aug 2952w high $17.8052w low $7.88
VCRESPY
Wall St. Highest PT $34.99 (+273.0%) Wall St. Avg PT $29.99 (+219.7%)
$9$18$27$36$46POC $12Hi $35Avg $30
Underwater Drawdown %Max DD -46.7%Current -42.3%
0.0%-46.7%
Relative Strength vs SPY-43.7% vs SPYUnderperforming
+58%0%-58%
1W
+$0.40 (4.45%)
1M
−$0.42 (4.29%)
3M
−$2.00 (17.57%)
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
2 analysts · mean score 1.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$9.38
Average target$29.99
+$20.61 (+219.7%) upsideaverage target vs current price
CurrentAverageMedian
Low$24.99
Median$29.99
High$34.99
12-month Wall Street target range
Recent analyst rating changes · 1
Initiated
2026-10-09 · Jefferies started covering VCRE at Buy
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$264.2M
52-week range$7.88 – $17.80
Revenue growth (latest quarter vs a year ago)+26.7%
Dividend yieldNo dividend
Analyst consensusStrong Buy (2)
Average analyst price target$29.99 (+220%)

What they do

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for VCRE yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

VCRE earningsNo upcoming date on file
Source: Yahoo Finance · refreshed 2026-10-24 03:06:08 ET
No EPS history available.

Quarterly revenue

QuarterRevenueYoY
2026-06-30$2.2M+148.1%
2026-03-31$602.0K–
2025-12-31$419.0K–
2025-06-30$1.7M–
2025-03-31$892.0K–

News & catalysts

More news
Vicore's Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results
ACCESS Newswire · Oct 22
Vicore Pharma to Participate in the Chardan Healthcare Conference
ACCESS Newswire · Oct 13
Jefferies Initiates Vicore Pharma Holding at Buy With $25 Price Target
MT Newswires · Oct 09
Increase in Number of Shares and Votes in Vicore Pharma
ACCESS Newswire · Sep 30
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
ACCESS Newswire · Sep 17
Rating changes
Initiated
2026-10-09 · Jefferies started covering VCRE at Buy

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 03:06:08 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026